Want to see ADGM full AI Analyst Report?
Top Page
Adagio Medical Holdings
(NASDAQ:ADGM)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.56
▼(-48.24% Downside)
Action:Reiterated
Date:06/17/26
The score is held down primarily by very weak financial performance (minimal revenue, ongoing sizable losses, and continued cash burn with rising leverage). Technicals also remain soft with the stock trading below key moving averages and negative MACD. Corporate events provide some offset via meaningful regulatory milestones, but are tempered by Nasdaq bid-price noncompliance risk.
Positive Factors
Regulatory progress: PMA submission for vCLAS
Submitting a PMA marks a structural advancement from investigational to potential commercial product. Supported by Breakthrough Device status, the PMA creates a clear regulatory pathway that, if approved, enables market access, reimbursement discussions, and durable revenue potential in specialized EP labs.
Negative Factors
Minimal revenue and persistent net losses
The company lacks meaningful product revenue and remains loss-making at scale. Persistent large losses relative to negligible sales indicate the business is not yet operating sustainably; this structural profitability gap increases reliance on external funding and raises execution risk through commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress: PMA submission for vCLAS
Submitting a PMA marks a structural advancement from investigational to potential commercial product. Supported by Breakthrough Device status, the PMA creates a clear regulatory pathway that, if approved, enables market access, reimbursement discussions, and durable revenue potential in specialized EP labs.
Read all positive factors
Adagio Medical Holdings (ADGM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.66M
Dividend YieldN/A
Average Volume (3M)152.12K
Price to Earnings (P/E)―
Beta (1Y)-0.30
Revenue Growth-100.00%
EPS Growth100.00%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.39
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap1.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-50.66
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$3.33Price Target Upside208.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Adagio Medical Holdings Business Overview & Revenue Model
Company Description
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but n...
How the Company Makes Money
null...
Adagio Medical Holdings Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
32
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 269.00K | 300.00K | 189.00K | 270.00K |
| Gross Profit | -431.00K | -684.00K | -1.67M | -1.01M | -686.00K | -888.00K |
| EBITDA | -20.43M | -21.21M | -53.48M | -35.95M | -23.04M | -19.60M |
| Net Income | -24.37M | -25.08M | -53.76M | -38.15M | -23.67M | -19.94M |
Balance Sheet | ||||||
| Total Assets | 39.31M | 43.25M | 48.45M | 6.83M | 8.70M | 21.44M |
| Cash, Cash Equivalents and Short-Term Investments | 12.91M | 17.11M | 20.59M | 1.38M | 5.55M | 18.85M |
| Total Debt | 24.09M | 21.76M | 16.27M | 38.40M | 9.80M | 0.00 |
| Total Liabilities | 33.58M | 30.85M | 28.54M | 138.85M | 104.57M | 94.06M |
| Stockholders Equity | 5.72M | 12.40M | 19.91M | -132.02M | -95.88M | -72.62M |
Cash Flow | ||||||
| Free Cash Flow | -15.60M | -19.39M | -31.11M | -25.98M | -22.90M | -20.58M |
| Operating Cash Flow | -15.93M | -19.01M | -29.46M | -25.65M | -22.41M | -19.31M |
| Investing Cash Flow | -41.00K | -374.00K | -1.65M | -340.00K | -500.00K | -1.27M |
| Financing Cash Flow | 16.13M | 16.13M | 15.63M | 21.88M | 9.53M | 130.00K |
Adagio Medical Holdings Technical Analysis
Negative
1.08
Price Trends
0.77
Negative
0.97
Negative
1.07
Negative
Market Momentum
-0.06
Negative
27.89
Positive
4.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADGM, the sentiment is Negative. The current price of 1.08 is above the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.77, and above the 200-day MA of 1.07, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 27.89 is Positive, neither overbought nor oversold. The STOCH value of 4.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADGM.
Adagio Medical Holdings Risk Analysis
Adagio Medical Holdings disclosed 78 risk factors in its most recent earnings report. Adagio Medical Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adagio Medical Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $52.53M | -0.68 | 239.44% | ― | 10.38% | 20.70% | |
46 Neutral | $12.66M | -0.42 | -312.04% | ― | -100.00% | 100.00% | |
46 Neutral | $9.62M | -0.08 | -164.92% | ― | -9.46% | 18.03% | |
46 Neutral | $40.09M | -0.14 | -49.65% | ― | -95.74% | -118.94% | |
45 Neutral | $6.00M | -0.19 | -335.47% | ― | 33.77% | -20.22% |
* Healthcare Sector Average
ADGM
Adagio Medical Holdings
0.57
-0.93
-62.00%
CODX
Co-Diagnostics
2.61
-5.35
-67.19%
PAVM
PAVmed
5.60
-12.02
-68.22%
VVOS
Vivos Therapeutics
0.43
-6.52
-93.78%
COCH
Envoy Medical
0.68
-0.88
-56.22%
Adagio Medical Holdings Corporate Events
Executive/Board ChangesShareholder Meetings
Adagio Medical Shareholders Approve Directors and Auditor Ratification
Positive
Jun 16, 2026
On June 16, 2026, Adagio Medical Holdings, Inc. held its 2026 Annual Meeting of Stockholders, with 72.35% of outstanding shares present or represented by proxy. Stockholders elected Orly Mishan and Sean Salmon as directors to serve until the 2029 ...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Adagio Medical Faces Nasdaq Minimum Bid Price Noncompliance
Negative
Jun 12, 2026
On June 12, 2026, Adagio Medical Holdings, Inc. disclosed that it had received a notice from Nasdaq stating its common stock no longer met the exchange’s $1.00 minimum bid price requirement over the prior 30 consecutive business days, trigge...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Adagio Files PMA for Breakthrough Ventricular Ablation System
Positive
May 21, 2026
On May 21, 2026, Adagio Medical Holdings submitted a Premarket Approval application to the U.S. Food and Drug Administration for its vCLAS Ventricular Ablation System, designed to treat drug-refractory, recurrent, sustained monomorphic ventricular...
Business Operations and StrategyProduct-Related Announcements
Adagio Medical Posts Strong Pivotal Results for VT Ablation
Positive
Apr 27, 2026
On April 26, 2026, Adagio Medical reported positive six‑month pivotal results from its FULCRUM‑VT IDE trial of the vCLAS ventricular ablation system in patients with ischemic and non‑ischemic structural heart disease. The study m...
Regulatory Filings and ComplianceShareholder Meetings
Adagio Medical Sets 2026 Annual Meeting, Proposal Deadlines
Neutral
Apr 20, 2026
Adagio Medical Holdings, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 16, 2026, with the specific time and location to be disclosed in its forthcoming definitive proxy statement. The company has set April 24, 2026, as the re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.